Overview

Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the pharmacokinetics (PK) of misoprostol acid for the MVI 200 in women requiring cervical ripening and induction of labor.

Phase:

Phase 2

Details

Lead Sponsor:

Ferring Pharmaceuticals

Treatments:

Misoprostol